{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+infusion&page=20", "query": { "intervention": "Continuous infusion", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 2658, "total_pages": 266, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+infusion&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+infusion&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T15:44:44.977Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05127590", "title": "RBN-2397 in Combination With Pembrolizumab in Patients With SCCL", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Squamous Non-Small Cell Lung Carcinoma" ], "interventions": [ { "name": "RBN-2397", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ribon Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 50, "start_date": "2022-03-15", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-10-21T15:44:44.977Z", "location_count": 4, "location_summary": "Newark, Delaware • Newnan, Georgia • Baton Rouge, Louisiana + 1 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Newnan", "state": "Georgia" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05127590" }, { "nct_id": "NCT02289690", "title": "Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Veliparib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 221, "start_date": "2014-10-13", "completion_date": "2019-04-17", "has_results": true, "last_update_posted_date": "2020-05-14", "last_synced_at": "2026-10-21T15:44:44.977Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Atlanta, Georgia + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02289690" }, { "nct_id": "NCT02291055", "title": "A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Cancer", "Cancer", "Head and Neck Cancer" ], "interventions": [ { "name": "ADXS11-001", "type": "DRUG" }, { "name": "MEDI4736", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advaxis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2015-04", "completion_date": "2020-11-20", "has_results": true, "last_update_posted_date": "2023-03-20", "last_synced_at": "2026-10-21T15:44:44.977Z", "location_count": 17, "location_summary": "Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02291055" }, { "nct_id": "NCT01364389", "title": "A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polymyalgia Rheumatica", "Inflammatory Diseases" ], "interventions": [ { "name": "AIN457", "type": "DRUG" }, { "name": "ACZ885", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 16, "start_date": "2011-02-14", "completion_date": "2013-01-29", "has_results": true, "last_update_posted_date": "2021-09-17", "last_synced_at": "2026-10-21T15:44:44.977Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01364389" }, { "nct_id": "NCT00967616", "title": "Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Neoplasms, Colorectal" ], "interventions": [ { "name": "CS7017", "type": "DRUG" }, { "name": "irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2009-09", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2020-05-04", "last_synced_at": "2026-10-21T15:44:44.977Z", "location_count": 6, "location_summary": "Beverly Hills, California • Fullerton, California • Washington D.C., District of Columbia + 3 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00967616" }, { "nct_id": "NCT00434850", "title": "Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Allogeneic Pancreatic Islet Cells", "type": "BIOLOGICAL" }, { "name": "Deoxyspergualin", "type": "DRUG" }, { "name": "Antithymocyte globulin", "type": "BIOLOGICAL" }, { "name": "Daclizumab or basiliximab", "type": "BIOLOGICAL" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 14, "start_date": "2006-10", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2016-03-16", "last_synced_at": "2026-10-21T15:44:44.977Z", "location_count": 3, "location_summary": "San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00434850" }, { "nct_id": "NCT00001427", "title": "A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "9-aminocamptothecin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 40, "start_date": "1995-01", "completion_date": "2000-04", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-21T15:44:44.977Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001427" }, { "nct_id": "NCT01088997", "title": "Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Persistent Fetal Circulation Syndrome" ], "interventions": [ { "name": "Milrinone Lactate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "10 Days", "sex": "ALL", "summary": "Up to 10 Days" }, "enrollment_count": 12, "start_date": "2010-06", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2016-07-12", "last_synced_at": "2026-10-21T15:44:44.977Z", "location_count": 2, "location_summary": "Detroit, Michigan • Philadelphia, Pennsylvania", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01088997" }, { "nct_id": "NCT00940524", "title": "Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Dasatinib, Mitoxantrone, Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2009-07", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-04-10", "last_synced_at": "2026-10-21T15:44:44.977Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00940524" }, { "nct_id": "NCT01181986", "title": "The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Exenatide SC", "type": "DRUG" }, { "name": "Exenatide IV", "type": "DRUG" }, { "name": "Placebo SC", "type": "DRUG" }, { "name": "Exendin-9", "type": "DRUG" }, { "name": "Placebo IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carl T. Hayden VA Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "35 Years to 70 Years" }, "enrollment_count": 76, "start_date": "2010-08", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2014-05-20", "last_synced_at": "2026-10-21T15:44:44.977Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01181986" } ] }